DirectorsTalk Interviews

DirectorsTalk

DirectorsTalk Interviews focus on financial markets and investment opportunities. The site features interviews with company directors, market analysts, and experts, offering insights into companies' performance, industry trends, and market updates. The content includes Q&A sessions, market commentary, and discussions about business developments, often highlighting the viewpoints of executives from publicly traded companies.

  1. -5 J

    TEAM plc CIO Flags 20% Plus Returns, AI Capex Doubts and Looming Inflation Shock

    Markets shrugged off political theatre and macro uncertainty to finish 2025 at record highs — but Craig Farley says the real story sits beneath the surface. In this conversation, the TEAM plc (LON:TEAM) Chief Investment Officer explains how a barbell equity approach, zero exposure to long-dated government debt, and a decisive allocation to precious metals powered 20 percent plus sterling returns. He also outlines why AI capex maths may not stack up, why Trump’s revived Monroe-style doctrine changes the geopolitical playbook, and how a second inflation wave could emerge just as investors grow complacent.Key Moments 00:30 – 2025 described as a year of stock market resilience despite US political drama01:05 – TEAM delivers 20%+ sterling returns across conservative, balanced and growth strategies01:40 – Early signs of AI fatigue and scrutiny of hyperscaler capex02:00 – Introduction of the “Don Roe doctrine” and its implications for foreign policy04:29 – $45bn AI revenues versus $650bn capex raises valuation concerns04:49 – Japan carry trade unwind risk and potential global spillovers05:40 – Prospect of unconventional US stimulus ahead of midterms06:07 – Increasing allocation to UK large caps amid style rotation07:16 – Portfolio positioning for 2026: tilt away from US mega-cap tech08:00 – Zero exposure to long-term government debt remains core stance TEAM plc is an international wealth, asset management and financial services group offering multi-asset investment solutions designed to grow and preserve client capital over the long term.

    9 min
  2. 10 FÉVR.

    Verici Dx: Tutivia Set to Disrupt Transplant Monitoring with Real-Time RNA Insights

    Verici Dx (LON:VRCI) is no longer just a diagnostics innovator—it’s a commercial-stage disruptor with momentum. In this interview, CEO Sara Barrington outlines how their flagship RNA-based test, Tutivia, is outperforming legacy transplant diagnostics, not only in validation trials but now in real-world use. With reimbursement locked in, early commercial traction, and a clear runway to capture a $900M addressable market, Verici Dx is positioned to redefine transplant care. Add in licensing success with Thermo Fisher (Clarava) and pipeline expansion toward fibrosis and urine-based diagnostics, and this is one growth story investors should be watching closely.Key Moments: 00:11 – Interview begins with Sara Barrington, CEO of Verici Dx00:38 – Focus on transplant diagnostics and AI-powered RNA testing01:53 – Why Verici started with kidney transplant and how Clarava (pre-transplant test) fits in02:48 – Tutivia’s role in post-transplant rejection detection04:05 – Overview of test pipeline and unmet clinical needs04:26 – What de-risked and ready for scale-up actually means05:26 – Reimbursement wins including Medicare and Palmetto coverage07:03 – Why validation was intentionally high-risk to gain clinical trust08:20 – Unmatched comprehensiveness vs competitors09:55 – Financial positioning and alignment with investor expectations11:03 – Capital focused on sales, marketing, and KOL engagement12:04 – $900M US market opportunity and Verici’s strategic entry points14:08 – Tutivia’s advantage in early-stage rejection vs. cell-free DNA rivals15:20 – Commercial ramp: scaling sales team from 4 to 1517:09 – Expected news flow: centre expansion, payer contracts, and commercial traction

    18 min

À propos

DirectorsTalk Interviews focus on financial markets and investment opportunities. The site features interviews with company directors, market analysts, and experts, offering insights into companies' performance, industry trends, and market updates. The content includes Q&A sessions, market commentary, and discussions about business developments, often highlighting the viewpoints of executives from publicly traded companies.